1-4 of 4
Sabine Zitzmann-Kolbe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Christoph A. Schatz, Sabine Zitzmann-Kolbe, Ingrid Moen, Monika Klotz, Shankari Nair, Stefan Stargard, Roger M. Bjerke, Katrine Wickstrøm Biseth, Yuan Zeng Feng, Bård Indrevoll, Veronique Cruciani, Jenny Karlsson, Bernard Haendler, Carsten H. Nielsen, Maria Z. Alfsen, Stefanie Hammer, Hartwig Hennekes, Alan Cuthbertson, Urs B. Hagemann, Åsmund Larsen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2531–2544.
https://doi.org/10.1158/1078-0432.CCR-23-3746
Published: 03 June 2024
View article titled, Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Open the PDF for Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Stefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, Simon Baumgart, Urs B. Hagemann, Arne Scholz, Bernard Haendler, Pascale Lejeune, Jenny Karlsson, Christine Ellingsen, Hartwig Hennekes, Carsten H. Nielsen, Mark U. Juul, Dominik Mumberg, Christoph A. Schatz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4367–4378.
https://doi.org/10.1158/1078-0432.CCR-21-0342
Published: 01 August 2021
View article titled, Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
Open the PDF for Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models in another window
Journal Articles

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Solene Geraudie, Derek Grant, Baard Indrevoll, Roger Smeets, Oliver von Ahsen, Alexander Kristian, Pascale Lejeune, Hartwig Hennekes, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Alan S. Cuthbertson, Dominik Mumberg
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (8): 1985–1996.
https://doi.org/10.1158/1078-0432.CCR-19-2268
Published: 15 April 2020
View article titled, Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Open the PDF for Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández-Montalván, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Stefan Prechtl, Simon J. Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Vera Pütter, Marion Hitchcock, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1404–1414.
https://doi.org/10.1158/1078-0432.CCR-18-0628
Published: 15 February 2019
View article titled, Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data